Optiver Holding B.V. Trims Stake in MorphoSys AG (NASDAQ:MOR)

Optiver Holding B.V. reduced its holdings in MorphoSys AG (NASDAQ:MOR) by 13.6% during the 4th quarter, Holdings Channel reports. The firm owned 124,410 shares of the company’s stock after selling 19,632 shares during the quarter. Optiver Holding B.V.’s holdings in MorphoSys were worth $1,232,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Quadrant Capital Group LLC lifted its position in MorphoSys by 204.8% during the fourth quarter. Quadrant Capital Group LLC now owns 5,572 shares of the company’s stock worth $55,000 after buying an additional 3,744 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in MorphoSys by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company’s stock worth $173,000 after purchasing an additional 4,421 shares in the last quarter. Henry James International Management Inc. acquired a new position in MorphoSys during the 4th quarter worth $426,000. Finally, TD Asset Management Inc grew its stake in MorphoSys by 153.8% during the 4th quarter. TD Asset Management Inc now owns 361,138 shares of the company’s stock worth $3,575,000 after purchasing an additional 218,870 shares in the last quarter. 18.38% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $18.25 price objective (up from $17.00) on shares of MorphoSys in a research report on Thursday, March 14th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.78.

MorphoSys Stock Performance

Shares of NASDAQ MOR traded up $0.06 during trading hours on Wednesday, reaching $18.20. The stock had a trading volume of 117,682 shares, compared to its average volume of 1,380,465. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 4.98. MorphoSys AG has a fifty-two week low of $4.18 and a fifty-two week high of $19.50. The firm has a 50-day moving average of $18.16 and a 200-day moving average of $14.38.

MorphoSys (NASDAQ:MOR) last posted its quarterly earnings data on Monday, April 29th. The company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($0.51) by ($1.73). The company had revenue of $29.86 million for the quarter, compared to analysts’ expectations of $48.99 million. MorphoSys had a negative net margin of 226.79% and a negative return on equity of 694.31%. As a group, equities research analysts expect that MorphoSys AG will post -2.43 earnings per share for the current fiscal year.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.